Author

B. Awuah

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:organoid / primary culture· 2 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

B. Stonaker· 2 shared E. B. Osei-Bonsu· 2 shared E. Cheng· 2 shared E. K. Adjei· 2 shared F. S. Aitpillah· 2 shared I. Kyei· 2 shared J. K. Oppong· 2 shared J. Nguyen· 2 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Stonaker

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition.

F. P. Madorsky Rowdo, R. Martini, S. E. Ackermann, C. P. Tang, M. Tranquile, A. Irizarry, I. Us, O. Alawa, J. E. Moyer, M. Sigouros, J. Nguyen, M. A. Assaad, E. Cheng, P. S. Ginter, J. Manohar, , M. L. Martin

The paper uses CRISPR-Cas9 screens in breast cancer organoids from African ancestry patients to identify essential kinases and show synergy between EGFR and FGFR1 inhibitors.

Cancer Research · Feb 1, 2025Peer-reviewedCancer Biology

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment

F. P. M. Rowdo, G. Xiao, G. F. Khramtsova, J. Nguyen, O. Olopade, R. Martini, B. Stonaker, R. Boateng, J. K. Oppong, E. K. Adjei, B. Awuah, I. Kyei, F. S. Aitpillah, M. O. Adinku, K. Ankomah, , J. Bargonetti

This study shows that tumor organoids with mutant p53 are more sensitive to the combination of PARP inhibitor and temozolomide than those with wild-type p53.

bioRxiv · Jun 22, 2023Cancer Biology